Subscribe to RSS
DOI: 10.1055/s-0030-1270511
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York
Extra-adrenal Pheochromocytoma in the Organ of Zuckerkandl: Diagnosis and Treatment Strategies
Publication History
received 13.10.2010
first decision 01.12.2010
accepted 22.12.2010
Publication Date:
03 March 2011 (online)
Abstract
Pheochromocytoma (PHEO) and paraganglioma (PGL) are rare catecholamine-secreting neuroendocrine tumors arising from chromaffin tissue and can occur within the adrenal medulla (PHEO) or extra-adrenal sites (PGL). The most common site for PGL is the organ of Zuckerkandl, extra-adrenal chromaffin tissue near the origin of the inferior mesenteric artery.We here present 2 patients with extra-adrenal PGL in the organ of Zuckerkandl, located by iodine-123-metaiodobenzylguanadine (123I-MIBG) scintigraphy and thereafter treated surgically or with iodine-131-metaiodobenzylguanadine (131I-MIBG). First, in a 15-year-old boy with clinical suspicion of PHEO, the diagnosis was established by biochemical evaluation and confirmed by further imaging studies, including CT and 123I-MIBG, as PGL in the Zuckerkandl organ. The tumor was completely resected by laparotomy. Second, in a 70-year-old woman presenting with progressive hypertension and palpitations, MR and 123I-MIBG revealed a singular tumor lesion with abnormal 123I-MIBG uptake in the Zuckerkandl organ. Due to severe general vascular disease, surgery was not performed and instead the patient underwent 131I-MIBG therapy. The patient showed a good symptomatic response with improvement of symptoms and no relevant side-effects of therapy.
Key words
extra-adrenal Pheochromocytoma - iodine-123-metaiodobenzylguanadine (123I-MIBG) - iodine-131-metaiodobenzylguanadine (131I-MIBG)
References
- 1 Adler JT, Meyer-Rochow GY, Chen H. et al . Pheochromocytoma: current approaches and future directions. Oncologist. 2008; 13 779-793
- 2 Armstrong R, Sridhar M, Greenhalgh KL. et al . Phaeochromocytoma in children. Arch Dis Child. 2008; 93 899-904
- 3 Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann NY Acad Sci. 2006; 1073 30-37
- 4 Chrisoulidou A, Kaltsas G, Ilias I. et al . The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007; 14 569-585
- 5 Fottner C, Helisch A, Anlauf M. et al . 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010; 95 2800-2810
- 6 Frankel F. Classics in oncology. A case of bilateral completely latent adrenal tumor and concurrent nephritis with changes in the circulatory system and retinitis: Felix Frankel, 1886. CA Cancer J Clin. 1984; 34 93-106
- 7 Giammarile F, Chiti A, Lassmann M. et al . EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008; 35 1039-1047
- 8 Greenblatt DY, Shenker Y, Chen H. The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma. Ann Surg Oncol. 2008; 15 900-905
- 9 Grunwald F, Ezziddin S. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2010; 40 153-163
- 10 Ishibashi N, Abe K, Furuhashi S. et al . Adverse allergic reaction to 131I MIBG. Ann Nucl Med. 2009; 23 697-699
- 11 Jacobson AF, Deng H, Lombard J. et al . 123I-Meta-Iodobenzylguanidine Scintigraphy for the Detection of Neuroblastoma and Pheochromocytoma: Results of a Meta-Analysis. J Clin Endocrinol Metab. 2010;
- 12 Lenders JW, Eisenhofer G, Mannelli M. et al . Phaeochromocytoma. Lancet. 2005; 366 665-675
- 13 Lumachi F, Tregnaghi A, Zucchetta P. et al . Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nucl Med Commun. 2006; 27 583-587
- 14 Luster M, Karges W, Zeich K. et al . Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging. 2010; 37 484-493
- 15 Manger WM. An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges. Ann NY Acad Sci. 2006; 1073 1-20
- 16 Manger WM. The vagaries of pheochromocytomas. Am J Hypertens. 2005; 18 1266-1270
- 17 Manger WM, Gifford Jr RW, Hoffman BB. Pheochromocytoma: a clinical and experimental overview. Curr Probl Cancer. 1985; 9 1-89
- 18 Mannelli M, Ianni L, Cilotti A. et al . Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol. 1999; 141 619-624
- 19 Maurea S, Cuocolo A, Reynolds JC. et al . Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med. 1993; 34 173-179
- 20 Nakabeppu Y, Nakajo M. Radionuclide therapy of malignant pheochromocytoma with 131I-MIBG. Ann Nucl Med. 1994; 8 259-268
- 21 Petri BJ, van Eijck CH, de Herder WW. et al . Phaeochromocytomas and sympathetic paragangliomas. Br J Surg. 2009; 96 1381-1392
- 22 Shulkin BL, Ilias I, Sisson JC. et al . Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann NY Acad Sci. 2006; 1073 374-382
- 23 Van Der Horst-Schrivers AN, Jager PL, Boezen HM. et al . Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas – experience and meta-analysis. Anticancer Res. 2006; 26 1599-1604
- 24 Waguespack SG, Rich T, Grubbs E. et al . A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2010; 95 2023-2037
- 25 Wyszynska T, Cichocka E, Wieteska-Klimczak A. et al . A single pediatric center experience with 1025 children with hypertension. Acta Paediatr. 1992; 81 244-246
- 26 Zuckerkandl E. Ueber Nebenorgane des Sympathicus im Retroperitonealraum des Menschen. Verhandl Anat Ges. 1901; 15 85-107
Correspondence
D. KahramanMD
Department of Nuclear
Medicine, University of Cologne
Kerpener Straße 62
50924 Köln
Phone: +49/221/478 4050
Fax: +49/221/478 6777
Email: deniz.kahraman@uk-koeln.de